Sanofi extends $180M to California T cell engager startup Kali
赛诺菲向加州T细胞连接剂初创公司Kali追加1.8亿美元投资

Sanofi is back in the T cell engager business after a couple years of fluctuating interest, extending its support to a relatively unknown California startup in a large upfront deal that also carries $1.05 billion in down-the-road potential.
在经历几年的兴趣起伏后，赛诺菲重返T细胞连接剂领域，并以一笔可观的首付款支持一家相对默默无闻的加州初创公司；该交易还包含高达10.5亿美元的后续里程碑潜在价值。